Enjoy complimentary customisation on priority with our Enterprise License!
About Fabry Disease
Fabry disease is an inheritable lysosomal storage disease characterized by the excessive accumulation of globotriaosylceramide (GL-3) in lysosomes. It results from a deficiency of a-Gal and can result in symptoms such as fatigue, angiokeratoma, tinnitus, kidney failure, heart disorders, and nervous system problems. Fabry disease results from mutations in the galactosidase (GLA) gene, resulting in decreased activity or complete absence of a-Gal. Fabry disease resulting from the decreased activity of the enzyme is called later-onset Fabry disease. This form of the disease can effect both males and females. The symptoms of this disease typically appear during adulthood and usually focus on a single organ. Fabry disease resulting from the complete absence of a-Gal results in a more severe form called classic Fabry disease. The classic form of the disease usually affects males. The disease symptoms usually starts in adolescence and include clouded eye lenses, skin lesions, pain, and reduced sweating. If untreated, the disease can lead to cardiac dysfunction, renal failure or stroke, often resulting in death during fourth or fifth decade of life.
TechNavio's analysts forecast the Global Fabry Disease market to grow at a CAGR of 18.08 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Fabry Disease market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various innovator drugs available in the market for the treatment of fabry disease.
TechNavio's report, the Global Fabry Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Fabry Disease market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Genzyme
• Shire
Other Prominent Vendors
• Amicus Therapeutics
• Green Cross Corporation
• ISU Abxis
• JCR Pharmaceuticals
• Protalix Biotherapeutics
Market Driver
• Special Provisions for Orphan Drugs
• For a full, detailed list, view our report
Market Challenge
• Limited Patient Population
• For a full, detailed list, view our report
Market Trend
• Regulatory Assistance in Emerging Countries
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
05.1 Lysosomal Storage Disorders
05.2 Fabry Disease
05.2.1 Etiology and Pathophysiology
05.2.2 Signs and Symptoms
05.2.3 Epidemiology
05.2.4 Inheritance Pattern
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Historical Analysis of Global Fabry Disease market
07.4 Five Forces Analysis
08. Market Segmentation by Cell Line Used for Manufacturing the Drug
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.3 Other Prominent Vendors and Future Vendors
18. Pipeline Analysis
18.1 Clinical Trial Analysis of Pipeline Candidates
18.1.1 AT1001
18.1.2 GZ402671
18.1.3 PRX-102
19. Fabry Registry
20. Key Vendor Analysis
20.1 Genzyme
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Product Segmentation by Revenue 2013
20.1.4 Product Segmentation by Revenue 2012 and 2013
20.1.5 Geographical Segmentation
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 Shire
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Geographical Segmentation by Revenue 2013
20.2.4 Business Strategy
20.2.5 Recent Developments
20.2.6 SWOT Analysis
21. Other Reports in this Series
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.